Alnylam’s KARDIA-3 Hypertension Trial Reaches Completion, Raising Key Questions for ALNY Investors
Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
KARDIA-3 tests Alnylam’s drug zilebesiran as add-on therapy for adults with high cardiovascular risk and hard-to-control high blood pressure. The official goal is to see if zilebesiran, on top of standard pills, improves blood pressure and safety, a key question as payers and doctors look for new options in resistant hypertension.
The study evaluates zilebesiran, an injectable drug that targets a liver pathway linked to blood pressure control. It is compared with a placebo injection, and both are added to patients’ usual blood pressure medicines, aiming to lower blood pressure more effectively without major side effects.
This is a Phase 2 trial, meaning it tests both how well the drug works and how safe it is in a mid-sized group. Patients are randomly assigned to zilebesiran or placebo, and neither the patients, doctors, nor study staff know who gets which treatment, reducing bias and making the results more reliable.
All patients continue on two to four standard blood pressure drugs, so the trial reflects real-world practice rather than a lab-only setting. The main purpose is treatment, not prevention or diagnosis, and the study uses a parallel design, where groups are treated at the same time and compared against each other.
The study was first submitted in mid-February 2024, signaling when the company formally registered the trial design. The latest update was filed on February 27, 2026, which matters because it shows that new information, including status changes and protocol refinements, has recently been added for investors and analysts.
The trial is now listed as completed, meaning patient follow-up and main data collection are done, though detailed results are not yet posted. Primary and final completion dates will mark when the company can process full data, move toward larger studies or filings, and potentially discuss timelines for broader development and partnerships.
For investors, this update reinforces zilebesiran as a key asset in Alnylam’s growing cardiovascular pipeline beyond rare disease. If the final data show strong and durable blood pressure lowering on top of standard drugs, it could support a premium pricing case and broaden Alnylam’s revenue base over time.
The stakes are high because large players, including Novartis and other cardiovascular leaders, are also pushing new blood pressure and cardio-metabolic drugs. Positive readouts could lift ALNY’s valuation and sentiment, while weak or mixed data would likely raise questions on the commercial potential and slow enthusiasm for this part of the story.
The KARDIA-3 study of zilebesiran as add-on therapy in high-risk hypertension is now completed and recently updated, and further details are available on the ClinicalTrials portal.
To learn more about ALNY’s potential, visit the Alnylam Pharmaceuticals drug pipeline page.
